Piper Sandler analyst Allison Bratzel assumes AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $20.
Piper Sandler Assumes AbCellera Biologics at Overweight, Announces Price Target of $20
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.